Sinobiopharma, Inc. Appoints New Chief Financial Officer and Director to the Board

NANTONG CITY, China, Sept. 29 /PRNewswire-Asia-FirstCall/ — Sinobiopharma,
Inc. (OTC Bulletin Board: SNBP) (”Sinobiopharma” or, the ”Company”) is
pleased to announce that it has appointed Mr. Xinjie (James) Mu as the new
Chief Financial Officer and as a director on the Board. Dr. Lequn Huang resigned as the Chief Financial Officer in order to make room for the
appointment of Mr. Mu.

Mr. Mu has more than twelve years experience in the financial field. Most
recently, Mr. Mu has been an independent consultant working for China based US
public companies. Prior to that, he was a Chief Financial Officer at Jingwei
International Limited (OTCBB: JNGW.OB). Prior to that, he served as a senior
accountant at Geller and Company in New York City. Mr. Mu is also a Director
of China Infrastructure Investment Corporation (NASDAQ: CIIC) since March 2008.
Fluent in Mandarin and English, Mr. Mu holds a Bachelor of Science degree from
Hebei University of Science and Technology, and a Master of Business
Administration from Baruch College at the City University of New York.

”We are greatly pleased to have Mr. Mu join the Company and we are sure
that his professional background and strong management skills will add
tremendous value to Sinobiopharma’s future endeavors,” stated Dr. Lequan
Huang, President and CEO of Sinobiopharma.

Separately, the Company announces that Mr. Martin Shen resigned as
director of the Board for personal reasons.

”On behalf of the Board of Directors and Sinobiopharma, I want to
personally thank Mr. Shen for his contributions to the Company and wish him
well,” said Dr. Lequn Huang, President and CEO of Sinobiopharma.

About Sinobiopharma

Sinobiopharma Inc. is a fully integrated and highly innovative
biopharmaceutical company engaged in the research and development, manufacture
and marketing of biopharmaceutical products in China, the world’s fastest
growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co.
Ltd. in China, the Company’s current therapeutic focus is on
anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include “forward-looking statements” regarding
Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such
forward looking statements are within the meaning of Section 27A of the
Securities Act of 1933, as amended, and section 21E of the United States
Securities and Exchange Act of 1934, as amended, and are intended to be
covered by the safe harbor created by such sections. Where Sinobiopharma, Inc.
expresses or implies an expectation or belief as to future events or results,
such expectation or belief is believed to have a reasonable basis. However,
forward-looking statements are subject to risks, uncertainties and other
factors, which could cause actual results to differ materially from future
results expressed, projected or implied by such forward-looking statements.
Sinobiopharma, Inc. does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.
SOURCE Sinobiopharma, Inc.